Fasting and Cancer: The Promise, the Evidence, and the Honest In-Between
Listen to this information anywhere by hitting play below:
The Biology: Why Fasting Makes Theoretical Sense
To understand why fasting has captured the attention of oncology researchers, you have to understand a concept called differential stress resistance. When we fast, normal healthy cells downshift into a protective, low-energy state. They essentially batten down the hatches…conserving resources, ramping up DNA repair mechanisms, and becoming more resilient to external insults like chemotherapy drugs (Nencioni et al., 2018).
Cancer cells, on the other hand, cannot do this. Their growth signals are permanently stuck in the “on” position. They keep consuming, keep dividing, and in doing so, become more vulnerable to the very treatments designed to destroy them (Di Biase et al., 2016; Buono & Longo, 2018).
Think of it this way. Imagine a forest preparing for a storm. The healthy trees pull their sap down into the roots, flex with the wind, and survive. But the invasive species…the ones growing recklessly, consuming all the nutrients…they snap. Fasting creates a kind
of metabolic storm, and the cancer cells are the invasive species that cannot adapt. The measurable metabolic shifts are consistent and well-documented. Fasting reduces insulin-like growth factor 1 (IGF-1), lowers circulating insulin and glucose levels, and drops leptin…all of which are growth signals that many cancers rely upon to thrive (Caffa et al., 2020; Salvadori et al., 2021). There is also emerging evidence of immune remodeling: a reduction in regulatory T-cells (which suppress immune responses) and
an increase in cytotoxic T-cell activity, which is precisely the kind of immune shift we want when fighting a tumor (Vernieri et al., 2021).
The biology, in a word, is elegant. So it is with the body…when given the right conditions, it often knows how to fight.
The Approaches: How Fasting Is Being Used
Not all fasting is the same, and this is an important distinction. The research literature describes several approaches, each with its own profile of feasibility and tolerability.
Short-term water-only fasting typically involves 24 to 72 hours of no caloric intake before and/or after chemotherapy cycles. This was among the first approaches studied and has shown good safety profiles in early trials (De Groot et al., 2020; Dorff et al., 2016). The challenge, of course, is that asking a cancer patient to eat nothing for two to three days is a big ask…and adherence can be a real issue.
Fasting-mimicking diets (FMDs) offer a more practical alternative. These are low-calorie (around 350 kcal/day), low-protein, low-sugar regimens maintained for several days per chemotherapy cycle. The body enters a fasting-like metabolic state without complete food deprivation. Valter Longo’s group has been the primary driver of FMD research, and adherence tends to be higher with this approach compared to strict water fasting (Blaze̅vits̅ et al., 2023; Caffa et al., 2020).
Intermittent fasting and time-restricted eating protocols vary widely…from alternate-day fasting to daily eating windows of 6 to 8 hours. These are less well-studied in the cancer context specifically, but the metabolic benefits overlap considerably with what we see in FMD research (Tiwari et al., 2022; Sucholeiki et al., 2024).
The honest truth is that protocol heterogeneity remains one of the biggest challenges in this field. Timing, duration, caloric content, and how these protocols interact with different chemotherapy regimens…all of these variables make cross-study comparisons difficult. We are still in the early stages of understanding which approach works best, for whom, and when.
The Evidence: What We Actually Know
Here is where I want to be very careful, because the gap between theoretical promise and clinical proof is real…and respecting that gap is what separates good medicine from wishful thinking.
What the Evidence Supports
Safety and feasibility: Multiple phase I and II trials have demonstrated that short-term fasting and FMDs are generally safe and well-tolerated in patients with adequate nutritional status. Adverse events have been mild and adherence reasonable (De Groot et al., 2020; Dorff et al., 2016; Xue et al., 2025). This is strong evidence and it matters…because any adjunctive therapy must first do no harm.
Reduced acute side effects: Several studies report that patients who fasted around chemotherapy experienced less fatigue, fewer gastrointestinal symptoms, and reduced weakness compared to those who ate normally (Nencioni et al., 2018; De Groot et al., 2020; Plotti et al., 2020). Some data also show hematological protection…less drop in red blood cell and platelet counts, and reduced DNA damage in white blood cells after chemotherapy (De Groot et al., 2020; Dorff et al., 2016).
Metabolic and immune modulation: The biomarker data is consistent. Fasting reliably lowers IGF-1, insulin, and leptin. It shifts the immune landscape toward greater antitumor activity. These are real, measurable changes (Caffa et al., 2020; Vernieri et al., 2021).
Tumor response signals: The DIRECT trial…a multicentre phase 2 study…showed improved radiological and pathological response rates in breast cancer patients who used an FMD during neoadjuvant chemotherapy (De Groot et al., 2020). There have also been case reports of exceptional, long-lasting remissions in advanced solid tumors using cyclic FMD combined with standard therapies (Ligorio et al., 2022). These are exciting signals.
Preclinical immunotherapy synergy: Animal studies suggest that fasting may enhance the efficacy of immunotherapy drugs by remodeling the tumor microenvironment and boosting immune cell infiltration (Cortellino et al., 2022). If this translates to humans, the implications would be profound.
Where the Evidence Falls Short
And now the part that requires intellectual honesty.
Several systematic reviews and meta-analyses have found no significant reduction in overall chemotherapy toxicity or improvement in survival endpoints when comparing fasting to standard care (Maes et al., 2025; Drexler et al., 2022; Ferro et al., 2023). The findings are inconsistent. Some studies report benefits, others find no meaningful difference. The sample sizes are small. The protocols vary. And most of the human data comes from pilot studies or case series rather than large, definitive randomized controlled trials.
There is also the question of refeeding. Animal data suggest that inappropriate timing or high-calorie diets immediately after a fast could actually exacerbate tumor-promoting pathways (Nencioni et al., 2018). This is a critical nuance…the how of returning to food after a fast may matter as much as the fast itself.
We do not yet have clear survival data. We do not yet have large enough trials to speak with certainty. And the research community knows this…which is why the call for larger, well-designed RCTs is echoed across nearly every major review in this space (Anemoulis et al., 2023; Clifton et al., 2021).
The Concerns: Who Should Not Fast
This is perhaps the most important section of this entire article.
Fasting is not appropriate for every cancer patient. Patients who are frail, malnourished, or at risk for cachexia or sarcopenia should not be fasting around treatment. The risk of accelerating muscle loss and nutritional decline in these patients is real and well-documented (Tiwari et al., 2022; De Groot et al., 2019; Caccialanza et al., 2019). This is not a theoretical concern…it is a clinical reality.
Any decision to incorporate fasting into a cancer treatment plan should involve careful assessment by the treating physician and ideally an oncology-trained dietitian or nutritionist. Nutritional status must be evaluated. Body composition should be considered. And the patient’s overall treatment trajectory has to factor into the decision. This is not something to try based on a blog post alone…it requires professional guidance and individualized care.
I say this not to discourage anyone but to protect them. The most promising therapies can cause harm when applied without wisdom.
From My Practice: What I Have Seen
I have had many patients over the years incorporate fasting protocols around their chemotherapy cycles. Some have used short-term water fasts, others have followed fasting-mimicking approaches. And what I can tell you from my own clinical experience…which I want to be clear is observation, not controlled data…is that patients who tolerate fasting well often see great results. They tend to report less fatigue, fewer GI side effects, and a subjective sense of recovering more quickly between cycles.
I have also seen cases where the treatment response itself seemed to benefit, though I am careful about attributing causation to any single variable in a complex oncology picture. Cancer treatment is never one thing. It is the chemotherapy, the nutrition, the mindset, the immune support, the sleep, the relationships, the spirit of the patient…all of it together.
What I will say is this: for the right patient…someone who is well-nourished, metabolically stable, and motivated…fasting can be a powerful supportive tool when done under proper supervision. I have walked alongside enough patients to believe that the biology we see in the lab does translate into something clinically meaningful for many people. But I have also seen enough to know that every patient is different, and what works beautifully for one person may not be appropriate for another.
Healing is always a partnership. And fasting, like any tool, works best when it is wielded with both courage and discernment.
Where We Go From Here
The most exciting frontier in this space may be the intersection of fasting with immunotherapy. Preclinical data show that fasting-mimicking diets can enhance the efficacy of immune checkpoint inhibitors while reducing their side effects (Cortellino et al., 2022). If this holds up in human trials, it could reshape how we think about combining metabolic interventions with the next generation of cancer therapies.
Other open questions include identifying which patient populations are most likely to benefit, establishing standardized protocols that can be compared across studies, and understanding the role of the gut microbiome in mediating fasting’s anticancer effects (Chen et al., 2025).
The research gaps are significant. Breast cancer dominates the clinical literature while colorectal, lung, and hematologic malignancies remain understudied across nearly every outcome measure. Survival data is sparse. Quality of life research outside of breast cancer is essentially nonexistent.
We need larger trials. We need standardized protocols. And we need the humility to let the evidence lead rather than outpace it. But we also need the courage to pursue what the biology is clearly telling us…that the body, when given the right metabolic environment, has a remarkable capacity to fight.
A Final Thought
I have often said that most plants require both light and dark to meet their furthest growth potential. So it is with us. Cancer is undeniably a season of darkness for anyone who walks through it. But within that darkness, there are interventions…some ancient, some cutting-edge…that may help the body remember what it was designed to do.
Fasting is one of those interventions. Not a cure. Not a guarantee. But a tool with real biological plausibility, growing clinical support, and the kind of elegant simplicity that often marks the deepest truths in medicine.
If you are considering fasting as part of your cancer care, please do so with your physician. Together, you can determine whether your body is in a place to benefit from this approach…and if so, how to implement it safely and wisely.
Vis Medicatrix Naturae…the healing power of nature. It lives in you.
References
Anemoulis, M., Vlastos, A., Kachtsidis, V., & Karras, S. (2023). Intermittent Fasting in Breast Cancer: A Systematic Review and Critical Update of Available Studies. Nutrients, 15. https://doi.org/10.3390/nu15030532
Blaževitš, O., Di Tano, M., & Longo, V. (2023). Fasting and fasting mimicking diets in cancer prevention and therapy. Trends in Cancer. https://doi.org/10.1016/j.trecan.2022.12.006
Buono, R., & Longo, V. (2018). Starvation, Stress Resistance, and Cancer. Trends in Endocrinology & Metabolism, 29, 271-280. https://doi.org/10.1016/j.tem.2018.01.008
Caccialanza, R., Aprile, G., Cereda, E., & Pedrazzoli, P. (2019). Fasting in oncology: a word of caution. Nature Reviews Cancer, 19, 177. https://doi.org/10.1038/s41568-018-0098-0
Caffa, I., Spagnolo, V., Vernieri, C., et al. (2020). Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature, 583, 620-624. https://doi.org/10.1038/s41586-020-2502-7
Chen, J., Su, R., He, Y., & Chen, J. (2025). Intermittent fasting inhibits the development of colorectal cancer in APCMin/+ mice through gut microbiota and its related metabolites. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1563224
Clifton, K., et al. (2021). Intermittent fasting in the prevention and treatment of cancer. CA: A Cancer Journal for Clinicians, 71, 527-546. https://doi.org/10.3322/caac.21694
Cortellino, S., Raveane, A., Chiodoni, C., et al. (2022). Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. Cell Reports, 40(8), 111256. https://doi.org/10.1016/j.celrep.2022.111256
De Groot, S., Lugtenberg, R., Cohen, D., et al. (2020). Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications, 11. https://doi.org/10.1038/s41467-020-16138-3
De Groot, S., Pijl, H., Van Der Hoeven, J., & Kroep, J. (2019). Effects of short-term fasting on cancer treatment. Journal of Experimental & Clinical Cancer Research, 38. https://doi.org/10.1186/s13046-019-1189-9
Di Biase, S., Lee, C., Brandhorst, S., et al. (2016). Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Cancer Cell, 30(1), 136-146. https://doi.org/10.1016/j.ccell.2016.06.005
Dorff, T., Groshen, S., Garcia, A., et al. (2016). Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer, 16. https://doi.org/10.1186/s12885-016-2370-6
Drexler, U., Dörfler, J., Von Grundherr, J., Erickson, N., & Hübner, J. (2022). Fasting during cancer treatment: a systematic review. Quality of Life Research, 32, 1427-1446. https://doi.org/10.1007/s11136-022-03300-1
Ferro, Y., Maurotti, S., Tarsitano, M., et al. (2023). Therapeutic Fasting in Reducing Chemotherapy Side Effects in Cancer Patients: A Systematic Review and Meta-Analysis. Nutrients, 15. https://doi.org/10.3390/nu15122666
Ligorio, F., Fucà, G., Provenzano, L., et al. (2022). Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. European Journal of Cancer, 172, 300-310. https://doi.org/10.1016/j.ejca.2022.05.046
Maes, J., Durieux, V., Liebmann, M., Salmon, M., & Preiser, J. (2025). Impact of intermittent fasting on patients with cancer undergoing chemotherapy and/or targeted therapies: a systematic review of the literature. Supportive Care in Cancer, 33. https://doi.org/10.1007/s00520-025-09907-7
Nencioni, A., Caffa, I., Cortellino, S., & Longo, V. (2018). Fasting and cancer: molecular mechanisms and clinical application. Nature Reviews Cancer, 18, 707-719. https://doi.org/10.1038/s41568-018-0061-0
Plotti, F., Terranova, C., Luvero, D., et al. (2020). Diet and Chemotherapy: The Effects of Fasting and Ketogenic Diet on Cancer Treatment. Chemotherapy, 65, 77-84. https://doi.org/10.1159/000510839
Salvadori, G., Zanardi, F., Iannelli, F., et al. (2021). Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape. Cell Metabolism, 33(11), 2247-2259.e6. https://doi.org/10.1016/j.cmet.2021.10.008
Sucholeiki, R., Propst, C., Hong, D., & George, G. (2024). Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment. Cancer Treatment Reviews, 126, 102725. https://doi.org/10.1016/j.ctrv.2024.102725
Tiwari, S., Sapkota, N., & Han, Z. (2022). Effect of fasting on cancer: A narrative review of scientific evidence. Cancer Science, 113, 3291-3302. https://doi.org/10.1111/cas.15492
Vernieri, C., Fucà, G., Ligorio, F., et al. (2021). Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discovery, 12, 90-107. https://doi.org/10.1158/2159-8290.cd-21-0030
Xue, M., Zhang, N., Dong, X., et al. (2025). The feasibility and safety of fasting-mimicking diet in breast cancer patients with chemotherapy in China. Breast Cancer Research and Treatment, 213, 313-323. https://doi.org/10.1007/s10549-025-07756-w